Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia

Abdel-Halim, 1978, Inhibition of prostaglandin synthesis in rat brain, Acta Pharmacol. Toxicol., 43, 266, 10.1111/j.1600-0773.1978.tb02264.x

Afagh, 1996, Localization and cell association of C1qB in Alzheimer's disease brain, Exp. Neurol., 138, 22, 10.1006/exnr.1996.0043

Aisen, 1997, Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies, Gerontology, 43, 143, 10.1159/000213842

Aisen, 2000, A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study, Neurology, 54, 588, 10.1212/WNL.54.3.588

Barger, 1995, Tumor necrosis factors α and β protects neurons against amyloid β-peptide toxicity: evidence for involvement of a kB-binding factor and attenuation of peroxide and Ca2+ accumulation, Proc. Natl. Acad. Sci., 92, 9328, 10.1073/pnas.92.20.9328

Bauer, 1997, Expression and regulation of cylooxegenase-2 in rat microglia, Eur. J. Biochem., 243, 726, 10.1111/j.1432-1033.1997.00726.x

Benveniste, 1998, Cytokine actions in the central nervous system, Cytokine Growth Factor Rev., 9, 259, 10.1016/S1359-6101(98)00015-X

Bruce, 1996, Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors, Nat. Med., 2, 788, 10.1038/nm0796-788

Campbell, 1993, Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6, Proc. Natl. Acad. Sci., 90, 10 061, 10.1073/pnas.90.21.10061

Cao, 1995, Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response, Brain Res., 697, 187, 10.1016/0006-8993(95)00839-I

Chao, 1994, Serum cytokine levels in patients with Alzheimer's disease, Clin. Diagn. Lab. Immunol., 1, 433, 10.1128/CDLI.1.4.433-436.1994

Clements, 1993, Nonsteroidal anti-inflammatory drugs (NSAIDs), 700

Collaço-Moraes, 1996, Cyclooxygenase-2 messenger RNA induction in focal cerebral ischemia, J. Cereb. Blood Flow Met., 16, 1366, 10.1097/00004647-199611000-00035

DeArmond, 1995, Safety profile of over-the-counter naproxen sodium, Clin. Ther., 17, 587, 10.1016/0149-2918(95)80036-0

Elmquiat, 1997, Intravenous lipopolysaccharide induced cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages, J. Comp. Neurol., 19, 176

Fagarasan, 1997, Plasma C3a levels in Alzheimer's disease, Alzheimer's Res., 3, 137

Ferrari, 1990, Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain, Eur. J. Pharmacol., 179, 25, 10.1016/0014-2999(90)90398-P

Feuerstein, 1994, Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha, Cereb. Brain Metab. Rev., 6, 341

Fiebich, 1997, Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells, J. Neurochem., 68, 704, 10.1046/j.1471-4159.1997.68020704.x

Finch, 1993, TGF-β1 is an organizer of responses to neurodegeneration, J. Cell. Biochem., 53, 314, 10.1002/jcb.240530408

Gecsy, 1987, Naproxen tolerability in the elderly: a summary report, J. Rheumatol., 14, 348

Hewett, 2000, Cyclooxygenase-2 contributes to N-methyl-d-aspartate-mediated neuronal cell death in primary cortical cell culture, J. Pharmacol. Exp. Ther., 293, 417

Hirst, 1999, Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system, Mol. Cell Neurosci., 13, 57, 10.1006/mcne.1998.0731

Ho, 1999, Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease, J. Neurosci. Res., 57, 295, 10.1002/(SICI)1097-4547(19990801)57:3<295::AID-JNR1>3.0.CO;2-0

Ho, L., Purohit, D., Haroutunian, V., Luterman, J.D., Willis, F., Naslund, J., Buxbaum, J.D., Aisen, P.S., Pasinetti, G.M., 2001. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer's disease dementia, Arch. Neurol., 58, 487–492.

Hull, 1996, Inflammatory mechanisms in Alzheimer's disease, Eur. Arch. Psychiatry Clin. Neurosci., 246, 124, 10.1007/BF02189112

Jiang, 1994, b-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain, J. Immunol., 152, 5050, 10.4049/jimmunol.152.10.5050

Kelley, 1999, Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2, Am. J. Pathol., 155, 1, 10.1016/S0002-9440(10)65199-1

Kujubu, 1991, TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue, J. Biol. Chem., 266, 12 866, 10.1016/S0021-9258(18)98774-0

Leverenz, 1999, Effect of chronic high-dose exogenous cortisol on hippocampal neuronal number in aged nonhuman primates, J. Neurosci., 19, 2356, 10.1523/JNEUROSCI.19-06-02356.1999

Lim, 2000, Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease, J. Neurosci., 20, 5709, 10.1523/JNEUROSCI.20-15-05709.2000

Lukiw, 1997, Cyclooxygenase 2 RNA message abundance stability and hypervariability in sporadic Alzheimer neocortex, J. Neurosci. Res., 50, 937, 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E

Luterman, 2000, Cytokine gene expression as a function of the clinical progression of Alzheimer's disease dementia, Arch. Neurol., 57, 1133, 10.1001/archneur.57.8.1153

Mackenzie, 1998, Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging, Neurology, 50, 986, 10.1212/WNL.50.4.986

McGeer, 1996, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies, Neurology, 47, 425, 10.1212/WNL.47.2.425

Minghetti, 1996, Interferon gamma and nitric oxide down-regulate lipopolysaccharide-induced prostanoid production in culturated rat microglial cells by inhabited cyclooxygenase-2 expression, J. Neurochem., 66, 1963, 10.1046/j.1471-4159.1996.66051963.x

Morimoto, 1998, Co-injection of beta-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons, Neuroscience, 84, 479, 10.1016/S0306-4522(97)00507-1

Morris, 1993, The clinical dementia rating (CDR): current version and scoring rules, Neurology, 43, 2412, 10.1212/WNL.43.11.2412-a

Mukherjee, 2000, The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease, J. Neuroimmunol., 105, 124, 10.1016/S0165-5728(99)00261-1

Naslund, 2000, Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline, JAMA, 283, 1571, 10.1001/jama.283.12.1571

O'Banion, 1992, cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase, Proc. Natl. Acad. Sci., 89, 4888, 10.1073/pnas.89.11.4888

Oda, 1995, Complement and beta-amyloid neurotoxicity in vitro: a model for Alzheimer disease, Alzheimer's Res., 1, 29

Oka, 1997, Induction of cyclooxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons, Neuroreport, 8, 1161, 10.1097/00001756-199703240-00020

Olney, 1997, Excitotoxic neurodegeneration in Alzheimer disease — new hypothesis and new therapeutic strategies, Arch. Neurol., 54, 1234, 10.1001/archneur.1997.00550220042012

Osaka, 1999, Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity, J. Cell. Biochem., 73, 303, 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2

Overall, 1962, Brief psychiatric rating scale, Psychol. Rep., 10, 799, 10.2466/pr0.1962.10.3.799

Pasinetti, 1996, Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system, Neurobiol. Aging, 17, 707, 10.1016/0197-4580(96)00113-3

Pasinetti, 1998, Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions, J. Neurosci. Res., 54, 1, 10.1002/(SICI)1097-4547(19981001)54:1<1::AID-JNR1>3.0.CO;2-M

Pasinetti, 1998, Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain, Neuroscience, 87, 319, 10.1016/S0306-4522(98)00218-8

Rogers, 1992, Immune-related mechanism of Alzheimer's disease pathogenesis, 147

Rogers, 1993, Clinical trial of indomethacin in Alzheimer's disease, Neurology, 43, 1609, 10.1212/WNL.43.8.1609

Rosen, 1984, A new rating scale for Alzheimer's disease, Am. J. Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356

Sairanen, 1998, Cycooxygenase-2 is induced globally in infarcted human brain, Ann. Neurol., 43, 738, 10.1002/ana.410430608

Scharf, 1999, A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease, Neurology, 53, 197, 10.1212/WNL.53.1.197

Stewart, 1997, Risk of Alzheimer's disease and duration of NSAID use, Neurology, 48, 626, 10.1212/WNL.48.3.626

Thore, 1996, Immunofluorescent localization of constitutive and inducible prostaglandin H synthase in ovine astroglia, J. Comp. Neurol., 367, 1, 10.1002/(SICI)1096-9861(19960325)367:1<1::AID-CNE1>3.0.CO;2-7

Vandenabeele, 1991, Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain?, Immunol. Today, 12, 217, 10.1016/0167-5699(91)90032-O

Vane, 1995, New insights into the mode of action of anti-inflammatory drugs, Inflamm. Res., 44, 1, 10.1007/BF01630479

Velazquez, 1997, Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis, Nat. Med., 1, 77, 10.1038/nm0197-77

Warner, 1999, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl. Acad. Sci., 96, 563, 10.1073/pnas.96.13.7563

Webster, 1997, Charge-based binding of complement component C1qB to the Alzheimer amyloid B-peptide, Am. J. Pathol., 150, 1531

Webster, 1997, Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease, Neurobiol. Aging, 18, 415, 10.1016/S0197-4580(97)00042-0

Webster, 1997, Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease, Neurobiol. Aging, 18, 415, 10.1016/S0197-4580(97)00042-0

Wood, 1993, Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1b or IL-1RA but increases in the associated acute phase proteins IL-6, a2-macroglobulin and C-reactive protein, Brain Res., 629, 245, 10.1016/0006-8993(93)91327-O

Wyss-Coray, 1997, Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease, Nature, 389, 603, 10.1038/39321

Yasojima, 1999, Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and protiens in human brain and peripheral organs, Brain Res., 830, 226, 10.1016/S0006-8993(99)01389-X

Yermakova, 1999, Cyclooxygenase-1 in human Alzheimer's and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons, J. Neuropathol. Exp. Neurol., 58, 1135, 10.1097/00005072-199911000-00003

Zapolska-Downar, 1999, Ibuprofen protects low density lipoproteins against oxidative modification, Life Sci., 65, 2289, 10.1016/S0024-3205(99)00496-8